CoreCap Advisors’s ADMA Biologics ADMA Stock Holding History

CoreCap Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$100	Sell	10 -24	-71%	-$222	﹤0.01%	3047
2026 Q2	$285	Hold	34	–	–	﹤0.01%	2954
2026 Q1	$306	Hold	34	–	–	﹤0.01%	2717
2025 Q4	$620	Buy	34 +24	+240%	+$404	﹤0.01%	2673
2025 Q3	$147	Buy	+10	New	+$171	﹤0.01%	2699
2025 Q2	–	Sell	-7	Closed	-$139	–	2765
2025 Q1	$139	Sell	7 -39,908	-100%	-$690K	﹤0.01%	3033
2024 Q4	$685K	Buy	39,915 +4,813	+14%	+$90.5K	0.03%	405
2024 Q3	$702K	Buy	+35,102	New	+$546K	0.03%	390

Other funds holding ADMA

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

Kings Path Partners Sugar Land, Texas $380M AUM 12.42% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

First Citizens Bank & Trust Raleigh, North Carolina $6.73B AUM 18.92% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

CoreCap Advisors's ADMA Position: Q3 2026 in Review

CoreCap Advisors reduced its ADMA Biologics (ADMA) stake by 71% in Q3 2026, selling an estimated $222 and leaving 10 shares worth $100. The position accounts for ﹤0.01% of the portfolio, ranked #3047.

CoreCap Advisors first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $702K in Q3 2024. 43 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

CoreCap Advisors held 10 shares of ADMA Biologics worth $100 as of Q3 2026.
CoreCap Advisors sold 24 ADMA Biologics shares in Q3 2026, an estimated $222.
ADMA Biologics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #3047 holding.
CoreCap Advisors first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
CoreCap Advisors's ADMA Biologics position peaked at $702K in Q3 2024.
43 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.